YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Cytek Biosciences, Inc.; Sysmex Europe SE Complementary Technologies Deliver an Integrated, End-to-End Clinical Flow Cytometry Workflow for Laboratories Across Europe Cytek Biosciences and Sysmex Europe CollaborateCytek Biosciences and Sys…
On August 5, Cytek Biosciences (NASDAQ:CTKB) reported financial results for the second quarter ended June 30, and the report reads like two different companies at once. Revenue climbed, margins widened, and the installed base of instrument…
Cytek Biosciences, Inc. FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conf…
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer - Wenbin Jiang Chief Financial Officer - William McCombe Investor Relations - Mark Meehan Full Conference Call Transcript…
Key Points Interested in Cytek Biosciences, Inc.? Here are five stocks we like better. Revenue increased 6% year over year to $48.1 million, driven by 18% U.S. growth, strong China performance, and gains in full spectrum profiling instrume…
* Cytek Biosciences press release [https://seekingalpha.com/pr/20608750-cytek-biosciences-reports-second-quarter-2026-financial-results] (CTKB [https://seekingalpha.com/symbol/CTKB]): Q2 GAAP EPS of -$0.09 in-line. * Revenue of $48.1M (+5.…
The market expects Cytek Biosciences, Inc. (CTKB) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the…
FREMONT, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the second quarter of 2026 after market close on Wednesda…
(RTTNews) - Cytek Biosciences, Inc. (CTKB), a cell analysis solutions company, announced the opening of a new innovation centre in Bellevue, Washington, marking the relocation of its previous Seattle-area operations to a dedicated facility…
FREMONT, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the opening of a new innovation center in Bellevue, Washington, marking the relocation of its previous…
NEW YORK, June 5, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 22, 2026, to coincide with the…
By Karen Roman Prenetics Global Limited (Nasdaq: PRE) confirmed its multi-year partnership with #1 New York Times bestselling author and award-winning podcast host of On Purpose, Jay Shetty, making him the first global ambassador outside t…
Image source: The Motley Fool. DATE Thursday, May 7, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Wenbin Jiang Chief Financial Officer — William McCombe Head of Investor Relations — Paul Goodson Full Conference Call Tra…
Cytek Biosciences logo Key Points Interested in Cytek Biosciences, Inc.? Here are five stocks we like better. Cytek reported Q1 2026 revenue of $44.1 million, up 6% year-over-year, driven by a 32% rebound in the U.S., rising recurring reve…
In the last week, the market has stayed flat, but over the past 12 months, it has risen by 29%, with earnings forecast to grow by 16% annually. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or n…
Over the last 7 days, the U.S. market has dropped by 2.3%, though it has shown a robust increase of 13% over the past year, with earnings projected to grow by 16% annually in the coming years. In such fluctuating conditions, identifying st…
FREMONT, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- One year after opening its 8,500-square-foot Singapore facility, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) is marking a major milestone in its Asia-Pacific (AP…
Cytek Biosciences logo Key Points Cytek posted a record Q4 revenue of $62.1 million (+8% YoY), driven by double‑digit growth in EMEA and APAC, a 208‑unit installed‑base expansion to 3,664 units, and product momentum (notably the Aurora Evo…
* Cytek Biosciences press release [https://seekingalpha.com/pr/20416626-cytek-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides] (CTKB [https://seekingalpha.com/symbol/CTKB]): Q4 GAAP EPS of -$0.34 misses…
FREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the fourth quarter and full year ended Decembe…
As of December 19, 2025, major stock indexes in the United States have shown a notable upswing, with the tech-heavy Nasdaq and benchmark S&P 500 posting weekly gains amid a continued rally in technology shares. This positive momentum in br…
FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced its inclusion on TIME’s 2026 list of America’s Growth Leaders. Presented in partnership with global da…
FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that its Cytek® Muse® Micro cell analyzer has been named Drug Discovery Solution of the Year in the 2025 BioTech Breakthrough Awards.…
FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. UBS Global Healt…
(RTTNews) - Several healthcare and medtech stocks staged notable rebounds in after-hours trading Wednesday, with gains driven by updated guidance, margin improvements, and signs of operational resilience despite mixed quarterly results. Rx…
Earnings Call Insights: Cytek Biosciences (CTKB) Q3 2025 MANAGEMENT VIEW * CEO Wenbin Jiang highlighted that "total revenue reached $52.3 million, representing a year-over-year increase of 2% compared to the same period in 2024." Jiang emp…
Image source: The Motley Fool. Date Wednesday, November 5, 2025 at 4:30 p.m. ET Call participants Chief Executive Officer — Wenbin Jiang Chief Financial Officer — William D. McCombe Investor Relations — Paul Goodson Need a quote from a Mot…
Image source: The Motley Fool. Date Wednesday, November 5, 2025 at 4:30 p.m. ET Call participants Chief Executive Officer — Wenbin Jiang Chief Financial Officer — William D. McCombe Investor Relations — Paul Goodson Need a quote from a Mot…
FREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amid the reduction of various government grant programs and global economic challenges that have tightened research funding, Cytek Biosciences, Inc. (Nasdaq: CTKB) is taking steps to ensur…
FREMONT, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2025 after market close on Wednesday, Novemb…
FREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operations and enhances service for its customers, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the relocat…
Alvotech ALVO shares rallied 8.6% in the last trading session to close at $8.7. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.7% loss o…
FREMONT, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- With cancer research and diagnostics driving the need for deeper, faster cellular insights, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its advance…
As the U.S. stock market reaches new heights, with major indices like the S&P 500 and Dow Jones Industrial Average closing at record levels, investors are keenly eyeing opportunities that may not be immediately obvious. Penny stocks, a ter…
Earnings Call Insights: Cytek Biosciences (CTKB) Q2 2025 MANAGEMENT VIEW * CEO Wenbin Jiang reported that "second quarter revenue in 2025 was $45.6 million, down $1 million or 2.2% compared to the second quarter of 2024." He highlighted "l…
Over the last 7 days, the market has remained flat, but it is up 17% over the past year with earnings forecasted to grow by 15% annually. In such a landscape, identifying stocks that combine affordability with growth potential can be parti…